Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with
lymphodepletion and high-dose interleukin 2 has shown reproducible objective response …

Adoptive T-cell therapy (ACT) using expanded autologous tumor-infiltrating lymphocytes
(TIL) and tumor antigen-specific T cell expanded from peripheral blood are complex but …

The treatment of metastatic melanoma patients with autologous tumor-infiltrating
lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in …

Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is gaining momentum and
demonstrating durable responses in patients with advanced melanoma. Although …

Purpose: Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) is
a promising treatment for metastatic melanoma unresponsive to conventional therapies. We …

Over the past few years melanoma incidence has been rising steadily, resulting in an
increase in melanoma related mortality. Until recently, therapeutic options for metastatic …

The use of autologous tumor-infiltrating lymphocytes (TILs) as an advanced cancer therapy
has been well documented since the late 1980s. Despite steady progress in the field, it …

Adoptive cell therapy (ACT) based on autologous T cell derived either from tumor as tumor-
infiltrating lymphocytes (TILs) or from peripheral blood is developing as a key area of future …

Adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) has shown
significant clinical benefit, but is limited by toxicities due to a requirement for post-infusion …

Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable
clinical responses in patients with metastatic melanoma, substantiated by recent positive …